US: Teva can’t block generic rival from market entry (Competition Policy International)

Teva Pharmaceuticals has reportedly lost a battle to have a generic form of its multiple sclerosis drug be blocked from entering the market 10 days before Teva’s patent expires.

According to reports, the Israel-based pharmaceutical company filed a lawsuit against the US Food and Drug Administration accusing the regulator of failing …read more

Source: Global Competition Law Blogs

Leave a Reply

Your email address will not be published. Required fields are marked *